LGND today
$311.26-$5.01 (-1.58%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourLeaning Bearish
1 hourAscending Triangle
15 minDescending Triangle
5 minBearish
Daily trend turns down below $250.37
Key levels
Resistance$317.64
Support$302.37
Support$281.74
Latest news & SEC filings
SEC FilingLigand Pharmaceuticals Inc filed an insider trading report (Form 4)
AnalystBarclays Lifts Its Target Price on Ligand Pharmaceuticals
AnalystBarclays keeps Overweight on Ligand Pharmaceuticals, lifts target to $350
All LGND news →About Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires and structures revenue-sharing rights tied to medicines developed by other drugmakers. It also owns the Captisol and NITRICIL technology platforms, which earn royalties when partners use them in approved products. Most revenue comes from royalties on partner product sales, supplemented by material sales and licensing fees. The company works with pharmaceutical partners that handle development, manufacturing, and commercialization.
Based on the company's 10-K filed Feb 27, 2026.
Nasdaq · Healthcare
LIGAND PHARMACEUTICALS INC (LGND)
What Is the Price Target for LGND?
SEPT Low Target
$262.00
SEPT Mid Target
$357.00
SEPT High Target
$402.00
Analyst Consensus
$357.00
Is LGND a Buy or Sell Right Now?
Thesis
- •Revenue growing 60.4% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LGND.
Start Free Trial →Is LGND Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$286.53
37
Moat Score
NONE
4/9
Piotroski Score
8.4
Altman Z-Score
What Is Smart Money Doing with LGND?
Insider Signal
SELLING
0 buys / 19 sells (90d)
Congress Signal
BUYING
4 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Aryeh Jason | director | Sale | 500 | $160K | Nov 10, 2026 |
| Aryeh Jason | director | Sale | 844 | $270K | Nov 10, 2026 |
| Aryeh Jason | director | Sale | 646 | $207K | Nov 10, 2026 |
| Aryeh Jason | director | Sale | 10 | $3K | Nov 10, 2026 |
| Aryeh Jason | director | Sale | 282 | $90K | Nov 4, 2026 |
| Aryeh Jason | director | Sale | 700 | $224K | Nov 2, 2026 |
| Reardon Andrew | officer | Buy | 5,000 | $261K | Nov 2, 2026 |
| Reardon Andrew | officer | Sale | 283 | $87K | Nov 2, 2026 |
| Reardon Andrew | officer | Sale | 708 | $218K | Nov 2, 2026 |
| Reardon Andrew | officer | Sale | 522 | $162K | Nov 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LGND Growth Story
Revenue YoY
60.4%
3yr Revenue CAGR
11.0%
EPS Growth YoY
2886.36%
FCF Growth YoY
-48.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for LGND
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LGND, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:37:38 | $311.95 | 1,000 | $$312K | BUY |
| 20:37:39 | $318.21 | 1,099 | $$350K | SELL |
| 18:28:55 | $325.25 | 1,421 | $$462K | SELL |
| 16:13:38 | $318.00 | 1,200 | $$382K | SELL |
| 15:02:47 | $311.83 | 1,006 | $$314K | SELL |
5 dark pool trades shown · $$1.8M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for LIGAND PHARMACEUTICALS INC (LGND) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LGND — frequently asked questions
What is LGND stock price today?
LIGAND PHARMACEUTICALS INC (LGND) is at $311.26, down 1.58% (-$5.01) at the Nov 13, 2026 close.
Why is LGND stock moving today?
Latest LGND news — Nov 12, 2026: Ligand Pharmaceuticals Inc filed an insider trading report (Form 4) · Nov 11, 2026: Barclays Lifts Its Target Price on Ligand Pharmaceuticals
Why did LGND stock move on Oct 29, 2026?
Ligand Pharmaceuticals reported third-quarter 2026 results, with adjusted earnings of $2.67 per share beating the $2.38 consensus and revenue of $78.700 million topping the $77.232 million projection. The company also raised its fiscal 2026 adjusted EPS guidance to $9.50-$9.75 from $9.00-$9.50, though it cut its sales forecast to $225 million-$250 million from $270 million-$310 million.
What is the LGND price target?
The average analyst price target for LGND is $357.00, ranging from $262 to $402, based on 9 analysts. Latest: Barclays maintains on Nov 11, 2026.
What do analysts rate LGND?
Analyst ratings for LGND: 0 Buy, 20 Hold, 0 Sell — consensus Hold.
Did LGND beat earnings?
LGND last reported on Oct 29, 2026: EPS $2.67 vs $2.33 expected — a beat of 14.6%.
What is LGND's P/E ratio?
LGND trades at a P/E of 124.7 vs a Healthcare average of 17.7.
Does LGND pay a dividend?
LGND does not currently pay a dividend.
How much debt does LGND have?
LIGAND PHARMACEUTICALS INC reported $1.1B of debt and $56M of cash (Sep 30, 2026).
What are LGND support and resistance levels?
Support: $302.37, $281.74, $250.37. Resistance: $317.64.
What are insiders doing with LGND?
Insider activity: SELLING, 0 buys and 19 sells in the last 90 days.
What is the latest news on LGND?
Nov 12, 2026: Ligand Pharmaceuticals Inc filed an insider trading report (Form 4) · Nov 11, 2026: Barclays Lifts Its Target Price on Ligand Pharmaceuticals · Nov 11, 2026: Barclays keeps Overweight on Ligand Pharmaceuticals, lifts target to $350